Table 2.
Therapies and procedures initiated by the hyperhidrosis cohort (n = 44,484)
| Therapy or procedure | Time (in months) to first occurrence of therapy or procedure, mean (SD)a | Incidence rates | PDCb, mean (SD) | ||
|---|---|---|---|---|---|
| Events | Person-years | Rate per person-years | |||
| Prescription-strength antiperspirants (n = 22,954) | 1.4 (6.3) | 57,756 | 83,472 | 0.69 | 0.13 (0.09) |
| Glycopyrronium cloth (n = 6)c | 28.7 (27.8) | 6 | 15 | 0.40 | |
| Oral systemic therapies (n = 5823) | 16.9 (19.1) | 40,965 | 22,709 | 1.80 | 0.30 (0.28) |
| Botulinum toxin A (n = 1104) | 15.1 (19.5) | 3683 | 4530 | 0.81 | |
| Microwave thermolysis (n = 58) | 19.9 (17.8) | 379 | 239 | 1.59 | |
| Suction curretage (n = 70) | 19.7 (18.2) | 105 | 279 | 0.38 | |
| Iontophoresis (n = 463) | 22.9 (20.8) | 1733 | 2097 | 0.83 | |
| Endoscopic thoracic sympathectomy (n = 85) | 15.0 (21.8) | 98 | 338 | 0.29 | |
PDC Proportion of days covered
aTimes do not account for variable follow-up period within sample
bPDC was calculated over 12 months for prescription medications and/or antiperspirants only
cGlycopyrronium cloth was not available in the USA until October 2018 (study included data through November 2018)